Talk:Anastrozole

message: The patent on Arimidex (RE36617) expires on 27 December 2009.
A randomized clinical trial comparing tamoxifen with anastrozole in post-menopausal women with early breast cancer (the ATAC Trial) has been running since 1996 and is due to finish by the end of 2009.  The long-term follow-up of the patients will be taken over by the LATTE Study.
The PI of the LATTE Study is Professor Jack Cuzick of Queen Mary, University of London.
The current Chair of the ATAC Steering Committee is Professor John Forbes (Newcastle, Australia).
Previous Chair:
Professor Aman Buzdar (Houston, Texas, USA) June 2005 to April 2007
Professor Tony Howell (Manchester, UK) June 2003 to June 2005
Professor Michael Baum (London, UK) 1996 to 2003
Norman21 (talk) 09:32, 14 October 2009 (UTC)
thread_title: Untitled

message: This drug is frequently used in the treatment of children with growth disorder to stop or slow the onset of puberty. The cause of the growth disorder is through hormones which may trigger the early onset of puberty. At the onset of puberty the bone growth plates begin to close. This can occur in children as young as 5 years old, so for children severely behind in growth, the opportunity for increased growth is diminished. Arimidex is shown to slow or stop this process.
Anastrozole is currently used (in boys) to slow or stop the closing of the growth plates while allowing puberty to advance normally.   Therefore, it's not a good treatment for Precocious Puberty.  Instead, it's a good treatment for boys whose bone ages are advancing too rapidly while they're on growth hormone replacement therapy for growth hormone deficiency (pituitary dwarfism.) I'm not arguing with the statements The cause of the growth disorder is through hormones which may trigger the early onset of puberty. At the onset of puberty the bone growth plates begin to close. This can occur in children as young as 5 years old, so for children severely behind in growth, the opportunity for increased growth is diminished.  That is correct, but it's not quite appropriate to this article since it's based on the use of Anastrozole for Precocious Puberty.
How about something like This drug is frequently used in the treatment of boys with growth hormone deficiency whose bone ages are advanced beyond their chronological ages. Due to the abnormally advancing bone age, the growth plates begin to close, so the opportunity for normal growth is diminished. Arimidex is shown to slow or stop this process without affecting the normal progress of puberty. Or maybe the word "frequently" should be omitted?
One reason I didn't go ahead and edit this paragraph is because I'm not sure if or how anastrozole is used in girls.  Can anyone comment on that here? CathyinTX (talk) 05:13, 18 June 2009 (UTC)
thread_title:  Usage for children 

message: Because this drug is off patent, it's unlikely that a material amount of capital will be available to conduct the appropriate research demonstrating its efficacy in reversing symptoms of metabolic syndrome; however, I have been conducting some limited clinical research (yet unpublished) on aromatase inhibitors as a means to reserve the testosterone conversion via adipose(visceral)fat to estrogen, which in turn self perpetuates by increasing insulin resistance and adipose fat deposits. (Certainly, endocrinology has given this self-perpetuating cycle a name, anyone know what I should be calling this phenomenon?) I would encourage anyone with any expertise in this subject matter to help review and expand the research into anastrozole as a drug therapy for use in reversing symptoms of metabolic syndrome in aging men.  RGK (talk) 20:50, 15 August 2013 (UTC)
thread_title:  Metabolic Syndrome 

message: See (forex) http://www.medscape.org/viewarticle/748708 for a summary. This news article is based on  Amir et al 2011, full journal article available at http://jnci.oxfordjournals.org/content/103/17/1299.full
I'm not active in this area, and pressed for time, but I think this should be added to this article, and/or Aromatase inhibitors and/or Tamoxifen  -- since it directly impacts those considering these classes of drugs. 
Also see  ATLAS: Tamoxifen Far Inferior to AIs in Years 6 to 10, a 2013 op-ed at the Clinical Oncology newsletter. Obviously this is still a controversial topic. --Pete Tillman (talk) 22:29, 24 August 2013 (UTC)
thread_title:   "Aromatase Inhibitors Toxicity Affects Overall Survival" 

message: This drug is sometimes prescribed for people on testosterone Replacement Therapy. Can this wiki be expanded to include this? 12.203.176.74 (talk) 20:49, 13 December 2021 (UTC)
thread_title:  Prescribed for people on TRT